ASCO 2026: ADAM trial Shows Improved Relapse-Free Outcomes with Adjuvant Avelumab in Stage III MCC

Results from the Phase III ADAM trial suggest improved relapse-free outcomes with adjuvant avelumab in patients with stage III Merkel cell carcinoma and lymph node metastases following local treatment. Shailender Bhatia, medical oncologist at the University of Washington and Fred Hutch Cancer Center, discusses the efficacy and exploratory analyses, the impact of non-MCC deaths on outcomes, and how these findings may support individualised decision-making in clinical practice.